• Publications
  • Influence
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Ruxolitinib provided significant clinical benefits in patients with myel ofibrosis by reducing spleen size, ameliorating debilitating myelofibrosis-related symptoms, and improving overall survival.
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
In a mouse model of JAK2V617F(+) MPN, oral INCB018424 markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppression effects.
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc
The Janus kinase 2 mutation, JAK2617V>F, is myeloid neoplasm-specific; its presence excludes secondary polycythemia, thrombocytosis, or bone marrow fibrosis from other causes. Furthermore, JAK2617V>F
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
INCB018424 was associated with marked and durable clinical benefits in patients with myelofibrosis for whom no approved therapies existed, and clinical benefits were associated with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myel ofibrosis.
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.
We present a review of critical concepts and produce recommendations on the management of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition,
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
ATRA plus ATO may serve as an alternative to chemotherapy in low-risk untreated APL and, when combined with GO, may improve outcome in high-risk patients.
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.
It is concluded that the JAK2 1849G>T mutation is common in Ph(-) MPD but not critical for transformation to the acute phase of these diseases and that it is generally rare in aggressive leukemias.
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
It is concluded that mutations in TET2, ASXL1, and IDH1 are common in sAML derived from a preexisting MPN, and the existence of other mutations yet to be identified that are necessary for leukemic transformation is indicated.
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy
Novel therapies for patients with GS are required as the frequency, presenting characteristics, and survival in patients with nonleukemic GS are described by conducting a review of all untreated patients presenting to the MD Anderson Cancer Center between January 1990 and June 2002.
Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia
Adult Burkitt‐type lymphoma (BL) and acute lymphoblastic leukemia (B‐ALL) are rare entities composing 1% to 5% of non‐Hodgkin lymphomas NHL) or ALL. Prognosis of BL and B‐ALL has been poor with